Avaliação da Segurança e Eficácia do Stent Coberto iCover para o Tratamento da Doença Oclusiva Aorto-ilíaca (iliCo)
Estudo observacional prospectivo, multicêntrico, não randomizado, de braço único para avaliar a segurança e a eficácia do stent coberto iCover para o tratamento da doença oclusiva aorto-ilíaca
The objective of this prospective, multi-center, non-randomized, single-arm observational study is to evaluate the safety and the efficacy of the iCover covered stent over a 24-month follow-up period for the treatment of de novo iliac occlusive lesions, defined by a significant vessel stenosis ≥70%, in patients with symptomatic arteriopathy of the lower limbs (Rutherford class 2 to 5).
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This is a prospective, single-arm, multinational, and multicenter study conducted to evaluate the safety and efficacy of the iCover covered stent for the treatment of de novo iliac occlusive lesions (common and/or external iliac arteries) in patients with symptomatic lower limb arteriopathy. The primary endpoint of the study is primary patency, defined as the absence of restenosis in the target lesion over a 12-month follow-up period in patients who did not undergo a reintervention on the target lesion. Restenosis is defined as a reduction in the luminal diameter of more than 50%, assessed either by duplex ultrasound (considered as a peak systolic velocity index ≥ 2.4 at the target lesion) or by angio-CT (multiplanar reconstruction). Secondary endpoints include: technical and procedural success rate, freedom from all major adverse events, incidence of procedure- or device-related major local complications at the treated lesion, rate of SAEs, major amputation rate at the target limb, primary sustained clinical improvement (improvement in Rutherford classification), primary and secondary patency rates, TLR and TVR rates, and changes in ABI, the Walking Impairment Questionnaire, and the EQ-5D questionnaire from baseline.
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
-
Berlin, Alemanha
- KEH Berlin
-
Rendsburg, Alemanha
- Imland Klinik Rendsburg
-
-
Baden-Wurttemberg
-
Bad Krozingen, Baden-Wurttemberg, Alemanha, 79189
- Herzzentrum Bad Krozingen
-
-
Rhineland-Palatinate
-
Kaiserslautern, Rhineland-Palatinate, Alemanha, 67657
- MVZ Kaiserslautern
-
-
Saxony
-
Leipzig, Saxony, Alemanha, 04103
- Universitätsklinikum Leipzig
-
-
-
-
-
Aalst, Bélgica
- Onze Lieve Vrouw Aalst
-
Bonheiden, Bélgica
- Imelda Bonheiden
-
Dendermonde, Bélgica
- Az Sint Blasius Dendermonde
-
Genk, Bélgica
- ZOL Genk
-
-
-
-
-
Barcelona, Espanha
- Hospital Universitari Germans Trias i Pujol
-
Barcelona, Espanha
- Hospital de Santa Creu i Sant Pau
-
Bilbao, Espanha
- Hospital de Cruces
-
Sabadell, Espanha
- Hospital Parc Taulí
-
-
-
-
-
Brest, França
- Centre Hospitalier Universitaire de Brest
-
Paris, França
- Hôpital Paris Saint Joseph
-
Paris, França
- CHU Pitié Salpêtrière
-
Pessac, França
- Hôpital privé Saint-Martin
-
Villeneuve-d'Ascq, França
- Hôpital privé Villeneuve d'Ascq
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Patients with symptomatic arteriopathy of the lower limbs (Rutherford class 2 to 5). Patients with de novo atheromatous aorto-iliac lesions.
According to the incidence of TASC II lesions, approximately 70% of the patients will be classified as TASC II A or B lesions, while the other 30% will be classified as TASC II C or D lesions.
Descrição
Inclusion criteria
- ≥ 18 years of age
- Rutherford clinical stage 2 to 5
- Significant (≥70%) stenosis of atheromatous iliac lesions evidenced by duplex scan, MRI CT angiography or arteriography
- De novo atheromatous lesion of the aortoiliac segment
- Patient informed about the study and collection of the patient's informed consent agreement Exclusion criteria
Subjects will not be eligible to participate in the study if any of the following conditions are present in the subject:
- Protected adult patients, guardianship, curatorship, safeguard of justice
- Woman with possibility of pregnancy
- Patient with asymptomatic atheromatous lesions
- Patient with inflow lesion in the infrarenal aorta
- Patient treated with Covered endovascular reconstruction of aortic bifurcation (CERAB reconstruction)
- Acute ischemia or acute thrombosis
- Non-atherosclerotic disease
- History of coagulopathy
- Severe comorbidities with life expectancy <2 years
- Contraindication to taking antiplatelet aggregation therapy (aspirin or clopidogrel). The patient must be able to take an antiplatelet aggregation for at least 3 months after the procedure
- Patient participating in another clinical study which may interfere with the results
- Comorbidity or any reason which, according to the investigator, could limit the participation, the patient's adherence with the follow-up or the scientific integrity of the study
- Lesion near or adjacent to an aneurysm
- Inability to follow-up during the investigation
- Patient objection to participate in the investigation
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
iCover covered stent
Percutaneous transluminal angioplasty (PTA) |
Percutaneous transluminal angioplasty (PTA) with iCover covered stent for the treatment of de novo aorto-iliac occlusive lesions |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Primary Patency
Prazo: 12 months after index procedure.
|
The primary patency, defined as the absence of restenosis in the target lesion over the 12-month follow-up period in patients who did not undergo a reintervention on the target lesion. |
12 months after index procedure.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Technical success rate
Prazo: Day 0.
|
Technical success rate, defined as the ability to cross and dilate the lesion and achieve residual angiographic stenosis no greater than 30% after iCover stent graft insertion. Outcomes will be computed as the percentage of lesions treated at the end of the procedure. |
Day 0.
|
|
Procedural success rate
Prazo: Day 0.
|
Procedural success rate, defined as technical success and no complications during the procedure including general and local complications as defined in the protocol. Outcomes will be computed as the percentage of patients at the end of the procedure. |
Day 0.
|
|
Freedom from All Major Adverse Event (MAEs)
Prazo: 1, 6, 12, 24 months after index procedure.
|
MAEs are described as All-Cause Mortality post-procedure, Target Lesion Revascularization (TLR) post-procedure and Major Amputation of the Target Limb post-procedure (amputations above the ankle of the target leg). |
1, 6, 12, 24 months after index procedure.
|
|
Incidence of Procedure- or Device- related Major Local Complications
Prazo: Up to 30 days after index procedure.
|
Incidence of Procedure- or Device- related Major Local Complications at the treated lesion or Puncture Site up to 30 days post-procedure. Major Local Complications include: Iliac arterial rupture, retroperitoneal hematoma, thrombosis of the iliac axis on the ipsilateral side, need for surgery to achieve hemostasis, bleeding with loss of more than 2 g/ dL of hemoglobin, false aneurysm at the puncture site, preventing resumption of walking at 24 hours or appearance of ischemia on the ipsilateral side. |
Up to 30 days after index procedure.
|
|
Rates of Serious Adverse Events (SAEs)
Prazo: 1, 6, 12, 24 months after index procedure.
|
Rates of SAEs, including both related and unrelated events. SAEs will be categorized as related or unrelated to the procedure/device based on adjudication by an Independent Clinical Events Committee. |
1, 6, 12, 24 months after index procedure.
|
|
Major amputation at target limb rate
Prazo: 1, 6, 12, 24 months after index procedure.
|
Percentage of patients with amputations above the ankle of the target leg will be counted. |
1, 6, 12, 24 months after index procedure.
|
|
Primary sustained clinical improvement
Prazo: 1, 6, 12, 24 months after index procedure.
|
Primary sustained clinical improvement defined as a sustained upward shift of 1 category of the Rutherford classification for patients with claudication, and by wound healing and rest pain resolution for patients in critical limb ischemia, without the need for repeated target lesion revascularization in surviving patients. |
1, 6, 12, 24 months after index procedure.
|
|
Primary patency rates
Prazo: 6 and 24 months after index procedure.
|
Primary patency rates, defined as the lack of restenosis without reintervention of the target lesion. Restenosis is defined as a reduction in the luminal diameter of more than 50%, determined by either, duplex ultrasound examination considered as a peak systolic velocity index ≥ 2.4 at the target lesion, or by angio-CT (multiplanar reconstruction). In case of death, the vessel is considered as patent as long as no restenosis was detected during the last visit before the patient died. Outcomes will be computed as the percentage of lesions (Time frame: 6, 24 months after index procedure). |
6 and 24 months after index procedure.
|
|
Secondary patency rates
Prazo: 6, 12, 24 months after index procedure.
|
Secondary patency rates, defined as the patency of the stent following an endovascular or surgical reintervention due to significant in-stent restenosis or occlusion. Outcomes computed as percentage of lesions. |
6, 12, 24 months after index procedure.
|
|
Target lesion revascularization (TLR) rate
Prazo: 1, 6, 12, 24 months after index procedure.
|
Target lesion revascularization (TLR) rate, defined as the need for repeated procedures (endovascular or surgical) due to a problem arising from the lesion initially treated in surviving patients with preserved limbs. Outcomes will be computed as the percentage of lesions. |
1, 6, 12, 24 months after index procedure.
|
|
Target vessel revascularization (TVR) rate
Prazo: 1, 6, 12, 24 months after index procedure.
|
Target vessel revascularization (TVR) rate, defined as the need for repeated procedures (endovascular or surgical) due to a problem arising remote from the vessel initially treated in surviving patients with preserved limbs. Outcomes will be computed as the percentage of lesions. |
1, 6, 12, 24 months after index procedure.
|
|
Change in Ankle-Brachial Index (ABI) from baseline
Prazo: 1, 6, 12, 24 months post-procedure.
|
Change in ABI from baseline. |
1, 6, 12, 24 months post-procedure.
|
|
Change in Walking Impairment Questionnaire from baseline
Prazo: 1, 6, 12, 24 months post-procedure.
|
The Walking Impairment Questionnaire values will be recorded and compared to the baseline values. This questionnaire is a validated tool to assess walking capability in patients with Peripheral Arterial Disease in different situations. |
1, 6, 12, 24 months post-procedure.
|
|
Change in quality of life from baseline
Prazo: 1, 6, 12, 24 months post-procedure.
|
Change in quality of life from baseline, as measured by EQ-5D. The EQ-5D Questionnaire values will be recorded and compared to the baseline values. It is a validated questionnaire to measure the quality of life based on 5 different parameters. Worst possible score in this study would be 0, best possible score would be 1. In addition, the patient indicates her/his current health on an analog scale from 0 (worst) to 100 (best). |
1, 6, 12, 24 months post-procedure.
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- iliCo Study
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .